About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

RIBOMIC Inc.(4591) Summary

4591
TSE Growth
RIBOMIC Inc.
85
JPY
+4
(+4.94%)
Apr 10, 1:58 pm JST
0.57
USD
Apr 10, 12:58 am EDT
Result
PTS
outside of trading hours
84.6
Apr 10, 1:51 pm JST
Summary Chart Historical News Financial Result
PER
PBR
1.22
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 10, 2025
Opening Apr 10, 9:03 am
90 JPY 0.61 USD
Previous Close Apr 9
81 JPY 0.55 USD
High Apr 10, 9:03 am
90 JPY 0.61 USD
Low Apr 10, 10:30 am
83 JPY 0.56 USD
Volume
830,200
Trading Value
0.07B JPY 0.49M USD
VWAP
85.79 JPY 0.59 USD
Minimum Trading Value
8,500 JPY 57 USD
Market Cap
3.79B JPY 0.03B USD
Number of Trades
214
Liquidity & Number of Trades
As of Apr 10, 2025
Liquidity
Slightly High
1-Year Average
461
1-Year High Jan 8, 2025
8,347
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 4, 2025 0 5,765,200
Mar 28, 2025 0 6,725,600
Mar 21, 2025 0 6,306,000
Mar 14, 2025 0 5,722,200
Mar 7, 2025 0 5,696,000
Company Profile
RIBOMIC Inc. is a drug discovery venture originating from the University of Tokyo. The company develops molecular targeted drugs utilizing RNA and collaborates with major pharmaceutical companies.
Sector
Pharmaceuticals
RIBOMIC Inc. is a biotech venture company specializing in the development of aptamer drugs (molecular targeted therapies) originating from the University of Tokyo. The company conducts innovative research and development of aptamer drugs using its proprietary "RiboART System" technology platform. Its main pipeline includes the clinical development of umedaptanib pegol for age-related macular degeneration and achondroplasia. RIBOMIC is also developing multiple aptamer drug candidates for conditions such as pulmonary arterial hypertension and proliferative vitreoretinopathy. In the ophthalmology field, the company has a joint research agreement with the University of Tokyo. Additionally, through collaborations with pharmaceutical companies and in-house drug discovery efforts, RIBOMIC aims to create treatments for diseases with high unmet medical needs.